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Abstract 
The buccoadhesive controlled release tablets of Losartan potassium 
were prepared by Wet granulation method using the Carbopol 934P, 
hydroxy propyl cellulose (HPC), sodium alginate and sodium CMC 
as bioadhesive polymer. The tablets were evaluated for the Pre-
compression Parameters and post compression parameter like 
bioadhesive strength, In vitro retention time, and In vitro drug 
release study. The thickness and weight of the tablets, respectively, 
ranges from 2.3 ± 0.01 and 2.5 ± 0.02 and the weight of tablets 
ranges from 148-152mg.The Formulation containing sodium CMC 
and Sodium alginate shows acceptable bioadhesive strength but 
erode respectively, with in 6 to 8 hours. The tablet formulation 
containing carbopol and HPC shows higher bioadhesive strength, 
sustained release of drug and sufficient In vitro retention time. The 
optimized formulation obeys the first order release kinetics. 
Key words: Losartan potassium, Buccoadhesive, Carbopol 934P, 
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Introduction 
Losartan is a competitive antagonist of 
angiotensin II and 10,000 times more selective 
for ATI and ATII receptor, does not block any 
other receptor or ion channel. Losartan is 
soluble in aqueous buccal fluids and used in 
treatment of hypertension; nephropathy in type 2 
diabetic patients; reduce risk of stroke in 
patients with hypertension and left ventricular 
hypertrophy. Oral absorption of losartan is not 
affected by food, but bioavailability is only 33% 
due to first pass metabolism. It partially 
carboxylase in liver to an active metabolite 
(E3174) which is a 10- 30 times more potent 
non competitive AT1 antagonist.[1]   
 
The plasma half life of losartan is 2 h, but that 
of E3174 is 6-9 h. Both the component are 98% 
plasma protein bond, do not enter the brain and 
excreted by the kidney. It has been suggested 
that drugs with biological half life in the range 
of 2-8 h are good candidates for sustained 
release formulation.[2]  
 
Sustained release formulation of losartan has 
become available. The short half life and severe 
first pass metabolism of losartan makes it 
suitable for administration via buccal drug 
delivery system that provides controlled drug 
delivery by passing first pass effect (N). The 
buccal route was chosen because of its good 
accessibility, robustness of the epithelium, facial 
removable of dosage form, relatively low 
enzyme activity, satisfactory patient acceptance 
and avoiding hepatic first pass metabolism.[3]  
 
Successful Buccal drug delivery system requires 
at least three of following: 
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A bioadhesive to retain the drug in the oral 
cavity and maximize the intimacy of contact 
with the mouth release the drug in controlled 
fashion under the conditions dominant in the 
mouth and overcome the low permeability of 
oral mucosa.[2,3] For the maximum retention 
time of dosage form in buccal cavity, suitable 
buccoadhesive polymer was selected and that 
polymer controlled the release of drug from the 
dosage form. 
 
The aim of study was to prepare Controlled 
release the buccoadhesive dosage form of the 
Losartan potassium by using the Carbopol 934P, 
HPC, sodium alginate and sodium CMC as 
buccoadhesive polymer. The buccoadhesive 
tablets were evaluated for the thickness, 
Bioadhesive strength, In vitro retention time and 
In vitro drug release study. 
 
Materials and Methods 
Materials 
Losartan potassium (Dr. Reddy’s 
Laboratories,Ltd), Carbopol (FMC 
Biopolymer), HPC (FMC Biopolymer), Sodium 
alginate (Aqualan), Sodium CMC (Aqualan), 
talc (Mukesh Chemicals (P) Ltd), Magnsium 
stearate NF (Signet), Disodium hydrogen 
phosphate (Merck), Potassium hydrogen 
phosphate (Merck), isopropyl alcohol (Fischer 
Scientific), Acetone (Fischer Scientific). 
 
Formulation of buccoadhesive tablets 
Buccoadhesive tablets were prepared by wet 
granulation method. All the materials were taken 
according to table no.1 in clean dispensing 
booth. Weight of the drug taken as per adjusted 
calculation for LOD and assay value. Drug, 
lactose, polymer are sifted through 60 mesh size. 
The talc and magnesium stearate are pass 
through mesh no.60. Sifted materials are 
transferred to a poly bag and mixed for 10 
minutes by hand shaking. The drug, lactose, and 
polymer are taken in an aluminium foil dish and 
few ml of IPA or acetone is added drop wise for 
preparing dough. IPA or acetone is added as a 
granulating fluid and hand granulation is 
performed. Wet mass is dried for complete 
removal of acetone or IPA or until LOD less 
than 2% W/W in tray drier. Dried granules are 
passed through 22 mesh for sizing. Granules are 
lubricated by addition of talc and magnesium 
stearate. Lubricated blend compressed by using 
8mm flat faced beveled edged with break line on 
one side using Cadmach compression machine. 
 
Table.1. Composition of Various Formulation 
Ingredients  F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 F-12 F-13 F-14 
Losartan 
potassium 
25 25 25 25 25 25 25 25 25 25 25 25 25 25 
Lactose 45.50 45.50 45.50 45.50 45.50 45.50 45.50 45.50 45.50 45.50 45.50 45.5 45.50 45.50 
Carbopol 
934P 
37.5 37.5 52.5 52.5 - - 30 30 45 45 22.5 22.5 - - 
HPC-EF 37.5 37.5 22.5 22.5 - - 45 45 30 30 52.5 52.5 - - 
Sod. CMC - - 
  
- - - - - - - - 75 75 
Sodium 
alginate 
- - - - 75 75 - - - - - - - - 
IPA Qs - Qs - Qs - Qs - Qs - Qs - Qs - 
Acetone - Qs - Qs - Qs - Qs - Qs - Qs - Qs 
Talc 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Magnesium 
stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total  150 150 150 150 150 150 150 150 150 150 150 150 150 150 
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Evaluation of physical properties of 
mucoadhesive tablets 
The thickness, hardness, weight uniformity were 
determined by in similar way as stated for 
conventional oral tablets in the accrediated 
pharmacopoeia. 
 
Drug contentment uniformity 
Drug content uniformity experiments were 
determined by the procedure stated in the US 
pharmacopoeia. 
 
Swelling studies[4] 
The swelling properties of tablet were evaluated 
by determination of % hydration. Each tablet 
was weighed (w1) and immersed in simulated 
saliva fluid at ph 6.8 for predetermined times    
(1, 2, 3, 4, 5, 6 and 7 h). After immersion for 
specified time, tablets were wiped off to remove 
excess of surface water by using filer paper and 
weighed (w2). Percentage hydration was 
calculated using following formulae 
                  % hydration = (w2-w1/w1) *100 
 
Detachment Stress 
This method is used to measure In vitro 
bioadhesive capacity of different polymers. It is 
a modified method developed by Mertti 
Marvole. This modified assembly is shown in 
Fig. 1. Procaine buccal mucosa was obtained 
from local slaughter house & stored in kreb’s 
buffer solution. The experiment was performed 
within the 3 h of procurement of mucosa. The 
procaine mucosa was washed with the distilled 
water & carefully tied to the glass slide with the 
help of thread. This portion was put in the 
petridish with a 6.8 buffer solution. During the 
experiment the solution was kept at 37°C.  The 
tablet was stuck on to the glass stopper by using 
cyano acrylate adhesive and that stopper tied 
with a thread. The other portion of that thread 
was tied to the plastic beaker. That tablet was put 
on mucosa by applying finger pressure for 30 s. 
After making contact between the tablet & 
mucosa for a fixed time of 3 s; the water was 
added through a pipe connected to a separating 
funnel containing water in a drop wise to that 
plastic beaker. The force needed to detach the 
tablet from the mucosa was measured.  
 
 
Fig 1. Instrument for Measurement of Bioadhesive 
Strength. 
 
In vitro retention time 
The In vitro retention time is one of the most 
important physical parameters for an adhesive 
formulation. The formulation was pressed over 
the excised porcine buccal mucosa for 30 s after 
previously being secured on a glass slab and 
was immersed in a beaker containing 500 ml of 
phosphate buffer, pH 6.8, at 37±2°C.One stirrer 
was fitted at a distance of  5cm from the tablet 
and rotated  at 25 rpm. The time for complete 
erosion or detachment of the tablet from the 
mucosa was noted. It is illustrated in the Fig.2.5 
 
 
Fig 2.Instrument for measurement of in vitro retention 
time. 
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Dissolution studies 
The release rate of losartan potassium 
bioadhesive tablets was determined using USP 
Dissolution Testing Apparatus II (Paddle type). 
The dissolution test was performed using 900 ml 
of 6.8 phosphate buffer, at 37 ± 0.5°C with 50 
rpm. Aliquot (10ml) of the solution was 
collected from the dissolution apparatus hourly 
for 8 hours and were replaced with fresh 
dissolution medium. The aliquots were filtered 
through Whatmann filter paper no. 41. 
Absorbance of these solutions was measured at 
233nm. Aliquots were withdrawn according to 
specified time interval from a zone midway 
between the surface of dissolution medium and 
the top of rotating paddle not less than 1 cm 
apart from the vessel wall. Cumulative 
percentage drug release was calculated using an 
equation obtained from a standard curve. Release 
studies were performed in triplicate.  
 
Stability study of optimized formulation 
To assess the drug and formulation stability, 
stability studies was performed according to ICH 
guideline. Optimized buccal tablets were sealed 
in aluminium packing and kept in humidity 
chamber maintained at 40°C and 75% RH for 
three months. Samples were analyzed for the 
drug content, bioadhesive strength and other 
physicochemical properties at regular intervals. 
 
Results and Discussion 
Physical characteristic of the tablets 
Buccoadhesive tablets were prepared by using 
the carbopol, HPC, sodium alginate and sodium 
CMC as mucoadhesive polymer because of his 
water uptake capacity, easy to stick the oral 
mucosa and sustained release of drug. The result 
of physical characteristic of the tablets of the 
losartan is shown in Table no.2. The weight and 
thickness o f the buccoadhesive tablets were 
with in the limit of the uniformity. The 
thickness of the tablets ranges from 2.3 ±0.01 
and 2.5 ±0.02 and the hardness of tablets ranges 
from 5.2 ±0.15 and 6.1 ±0.23. Hardness of the 
Bioadhesive tablets varied with various type and 
ratio of the Bioadhesive polymers. Tablets 
containing carbopol shows higher hardness 
compared to the other polymer. The difference 
in the tablets hardness did not affect the release 
of the drug from the hydrophilic matrices which 
is release by diffusion through the gel layer and 
erosion of this layer and is therefore 
independent of the dry state of the tablet. 
 
 
Table.2. Data of Tablet Evaluation Tests. 
Batch 
Code Thickness in mm 
Diameter 
in mm 
Hardness 
(kg/cm2) Friability (%) 
Content 
Uniformity (%) 
F 1 2.3 ±0.03 8.34 ±0.03 5.5 ±0.15 0.41 ± 0.02 94 ±0.04 
F 2 2.5 ±0.02 8.32±0.03 5.7 ±0.35 0.33 ±0.02 92 ±0.02 
F 3 2.4 ±0.03 8.23 ±0.02 6 ±0.28 0.38 ±0.07 97 ±0.1 
F 4 2.3±0.02 8.3 ±0.01 5.5±0.26 0.62 ±0.05 96 ± 0.08 
F 5 2.3 ±0.01 8.3 ±0.01 6.1 ±0.23 0.59 ±0.01 92 ± 0.09 
F 6 2.5 ±0.05 8.2 ±0.05 5.5 ±0.32 0.33 ±0.04 94 ± 1.2 
F 7 2.35 ±0.03 8.3 ±0.03 5.3 ±0.36 0.38 ±0.05 95 ± 1.5 
F 8 2.4 ±0.05 8.2 ±0.05 5.2 ±0.15 0.47 ±0.01 91 ± 0.08 
F 9 2.4±0.03 8.3±0.01 5.5 ±0.26 0.28 ±0.02 97 ±0.03 
F 10 2.3±0.04 8.2±0.05 5.5  ±0.4 0.33 ±0.02 96 ±0.13 
F 11 2.3±0.03 8.3±0.02 6 ±0.17 0.46 ±0.05 91  ±1.2 
F 12 2.34±0.02 8.2±0.02 5.7 ±0.35 0.33 ±0.02 95 ±0.09 
F 13 2.3±0.02 8.2±0.01 5.5 ±0.36 0.42 ±0.02 94 ±0.04 
F 14 2.3±0.03 8.3±0.02 5.4 ±0.28 0.33 ±0.05 95 ±0.03 
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In vitro drug release studies 
The release of losartan potassium from 
bioadhesive tablets varied according to the type 
&ratio of matrix forming polymers. The drug 
release was governed by the amount of matrix 
forming polymer. The most important factor 
affecting the rate of release from the buccal 
tablets is the drug : polymer ratio. An increase 
in polymer concentration causes an increase in 
the viscosity of the gel as well as formation of a 
gel layer with a longer diffusional path. This 
could cause a decrease in the effective diffusion 
coefficient of the drug and therefore a reduction 
in the drug release rate. 
 
Formulation F1-F2 containing carbopol 934 & 
HPC showed less drug release. Formulations 
F5-F6 containing sodium alginate eroded in 7h 
& F13-14 containing sodium CMC eroded in 6 
h. Formulation F3 & F4 containing greater 
amount of carbopol and lesser amount of HPC 
showed % release within acceptable limits, F11 
& F12 containing greater amount of HPC and 
lesser amount of carbopol showed % release 
within acceptable limits. Formulation F7, F8, F9 
& F10 showed medium % release. Losartan 
potassium concentration can be maintained in its 
effective range with help of a buccal delivery. 
The release mechanism of the optimized 
formulation obeyed first order release kinetics. 
Results are shown in Fig.3. 
 
In vitro bio adhesive strength study 
The results of the bioadhesion strength of 
losartan potassium buccal tablets are given in 
Table.3. In all the formulations, as the polymer 
concentration increased, work of adhesion 
increased. The order of bioadhesion was HPC < 
sodium alginate < sodium CMC < Carbopol 
934P. Buccal tablets formulated with Carbopol 
934 and HPC showed stronger mucoadhesion. 
Very strong bioadhesion could damage the 
epithelial lining of the buccal mucosa. 
 
 
Fig.3. Comparison of Dissolution Profiles of Various Formulations (series 1-14 means formulation 
no.1-14) 
Muthumanikandar et al. International Journal of Drug Delivery 3 (2011) 465-471 
 
 
 
470
Table.3. Detachment Study of bioadhesive 
tablets 
Formulations Detachment force (Dynes) 
F1 18.1 ±0.45 
F2 17.7 ±1.01 
F3 25.7 ±1.21 
F4 23.3 ±1.8 
F5 20.6 ±0.2 
F6 17.5 ±0.5 
F7 18.2 ±0.8 
F8 16.9 ±0.65 
F9 16.2 ±1.36 
F10 16.1 ±1.26 
F11 21.6 ±0.3 
F12 21.2 ±0.2 
F13 15.2 ±.16 
F14 15.1 ±.06 
 
In vitro retention time  
In vitro retention time, the formulation 
containing greater amount of polymers shows 
greater retention time means amount of 
polymers present in the formulation 
proportional to the In vitro retention time. In 
this study, formulation no. 1, 2, 3, 4 contain 
greater amount of polymers showing greater 
retention time. Formulation no. 11-14 contains 
lesser amount of polymers showing lesser 
retention time. Also, formulation no. 5-10 
shows in less retention time. 
 
Therefore it can be concluded that stable 
formulation could be develop by incorporating  
carbopol and HPC in 30% : 20% for sustaining 
release of Losartan Potassium from bioadhesive 
tablet with adequate bioadhesiveness and 
swelling properties without the risk of mucosal 
damage. It can be concluded that Losartan 
potassium buccal tablet can be convenient daily 
dosage form which can improve patient’s 
compliance. 
 
Table.4. In vitro retention time 
Formulation 
code 
Time (h) Formulation 
code 
Time (h) 
1 6.35±0.187 8 5.04±0.432 
2 6.16±0.534 9 4.44±0.321 
3 7.36±0.267 10 4.61±0.542 
4 6.55±0.452 11 5.24±0.432 
5 3.11±0.621 12 5.32±0.332 
6 2.58±0.234 13 3.50±0.234 
7 5.24±0.348 14 3.24±0.444 
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